Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel L Suzman

Showing results (1-10 of 45) with videos related to

Pageof 5
Sort By:
Oncology (Williston Park, N.Y.)|October 18, 2014
In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? Yes; we must beware of drawing conclusions from a subset analysisDaniel L Suzman, Emmanuel S Antonarakis
Clinical Genitourinary Cancer|December 17, 2013
High-dose itraconazole as a noncastrating therapy for a patient with biochemically recurrent prostate cancerDaniel L Suzman, Emmanuel S Antonarakis
Therapeutic Advances in Medical Oncology|July 25, 2014
Castration-resistant prostate cancer: latest evidence and therapeutic implicationsDaniel L Suzman, Emmanuel S Antonarakis
European Urology|October 26, 2013
Determining the optimal treatment for metastatic castration-resistant prostate cancer: age should not be a factorDaniel L Suzman, Mario A Eisenberger
Cancers|October 2, 2015
Clinical Implications of Hedgehog Pathway Signaling in Prostate CancerDaniel L Suzman, Emmanuel S Antonarakis
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2015
Does degree of androgen suppression matter in hormone-sensitive prostate cancer?Daniel L Suzman, Emmanuel S Antonarakis
Cancer Metastasis Reviews|January 9, 2014
Bone-targeting agents in prostate cancerDaniel L Suzman, Sosipatros A Boikos, Michael A Carducci
Liver International : Official Journal of the International Association for the Study of the Liver|April 1, 2018
Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agentsDaniel L Suzman, Lorraine Pelosof, Amy Rosenberg, et al.
Seminars in Oncology|April 12, 2017
Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST version 1.1-defined disease progression in clinical trialsDickran Kazandjian, Patricia Keegan, Daniel L Suzman, et al.
The Prostate|July 24, 2014
Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abirateroneDaniel L Suzman, Brandon Luber, Michael T Schweizer, et al.
Pageof 5

Showing results (1-10 of 45) with videos related to

Sort By:
Pageof 5
Oncology (Williston Park, N.Y.)|October 18, 2014
In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? Yes; we must beware of drawing conclusions from a subset analysisDaniel L Suzman, Emmanuel S Antonarakis
Clinical Genitourinary Cancer|December 17, 2013
High-dose itraconazole as a noncastrating therapy for a patient with biochemically recurrent prostate cancerDaniel L Suzman, Emmanuel S Antonarakis
Therapeutic Advances in Medical Oncology|July 25, 2014
Castration-resistant prostate cancer: latest evidence and therapeutic implicationsDaniel L Suzman, Emmanuel S Antonarakis
European Urology|October 26, 2013
Determining the optimal treatment for metastatic castration-resistant prostate cancer: age should not be a factorDaniel L Suzman, Mario A Eisenberger
Cancers|October 2, 2015
Clinical Implications of Hedgehog Pathway Signaling in Prostate CancerDaniel L Suzman, Emmanuel S Antonarakis
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2015
Does degree of androgen suppression matter in hormone-sensitive prostate cancer?Daniel L Suzman, Emmanuel S Antonarakis
Cancer Metastasis Reviews|January 9, 2014
Bone-targeting agents in prostate cancerDaniel L Suzman, Sosipatros A Boikos, Michael A Carducci
Liver International : Official Journal of the International Association for the Study of the Liver|April 1, 2018
Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agentsDaniel L Suzman, Lorraine Pelosof, Amy Rosenberg, et al.
Seminars in Oncology|April 12, 2017
Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST version 1.1-defined disease progression in clinical trialsDickran Kazandjian, Patricia Keegan, Daniel L Suzman, et al.
The Prostate|July 24, 2014
Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abirateroneDaniel L Suzman, Brandon Luber, Michael T Schweizer, et al.
Pageof 5